Research progress on the relationship between EGFR-TKI resistance and p53 mutation in non-small cell lung cancer

doi:10.11958/20252986

Abstract

Abstract:

The main reason for the failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung cancer (NSCLC) is targeting drug resistance, and the main cause of drug resistance is the mutation of the tumor suppressor gene p53. How to prevent or reverse p53 mutations to solve the problem of EGFR-TKI resistance in advanced NSCLC has become a research hotspot in this field. This article summarizes the common mutation types of p53 and their related mechanisms affecting EGFR-TKI resistance, as well as how to intervene in p53 mutations to reverse EGFR-TKI resistance, and conducts an in-depth discussion on the relationship between EGFR-TKI resistance and p53 mutations in NSCLC patients.

Key words: carcinoma, non-small-cell lung, genes, p53, mutation, EGFR-TKI

CLC Number:

R734.2

References 34

[1]	ABUKHALIL A D, MANSOUR K, ALHAJ W, et al. Non-small cell lung cancer (NSCLC): characteristics,risk factors,molecular profile patterns,and treatment - a retrospective cohort study from Palestine[J]. J Egypt Natl Canc Inst, 2025, 37(1):40. doi:10.1186/s43046-025-00298-8.
[2]	SPINI A, GINI R, ROSELLINI P, et al. First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC:a real-life setting study with gender prospective[j]. cancers (basel), 2021, 13(23) doi:10.3390/cancers13236129.
[3]	ZHANG J, VOKES N, LI M, et al. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment[J]. Chin Med J Pulm Crit Care Med, 2024, 2(3):151-161. doi:10.1016/j.pccm.2024.08.002.
[4]	CASWELL D R, GUI P, MAYEKAR M K, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance[J]. Nat Genet, 2024, 56(1):60-73. doi:10.1038/s41588-023-01592-8.
[5]	HAN B, FEINSTEIN T, SHI Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen(DUBLIN-3):a phase 3,international,multicentre,single-blind,parallel group,randomised controlled trial[J]. Lancet Respir Med, 2024, 12(10):775-786. doi:10.1016/S2213-2600(24)00178-4.
[6]	VOKES N I, CHAMBERS E, NGUYEN T, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol, 2022, 17(6):779-792. doi:10.1016/j.jtho.2022.02.011.
[7]	IBUSUKI R, IWAMA E, SHIMAUCHI A, et al. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer[J]. NPJ Precis Oncol, 2024, 8(1):60. doi:10.1038/s41698-024-00557-2.
[8]	CHEN X, XIE L, QIAO K, et al. The pan-cancer analysis identified DIAPH3 as a diagnostic biomarker of clinical cancer[J]. Aging (Albany NY), 2023, 15(3):689-704. doi:10.18632/aging.204459.
[9]	MONDAL P, ROY K S, BHAGAT S V, et al. Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells[J]. FEBS Lett, 2024, 598(12):1532-1542. doi:10.1002/1873-3468.14890.
[10]	CHEN X, ZHANG T, SU W, et al. Mutant p53 in cancer:from molecular mechanism to therapeutic modulation[J]. Cell Death Dis, 2022, 13(11):974. doi:10.1038/s41419-022-05408-1.
[11]	ALSULAMI A F. Mutational disruption of TP53:a structural approach to understanding chemoresistance[J]. Int J Mol Sci, 2025, 26(18):9135. doi:10.3390/ijms26189135.
[12]	BRAND T M, DUNN E F, IIDA M, et al. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab[J]. Cancer Biol Ther, 2011, 12(5):436-446. doi:10.4161/cbt.12.5.16394.
[13]	ZHAO Y, ZHOU K, XIA X, et al. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells[J]. Cell Cycle. 2023, 22(2):200-212. doi:10.1080/15384101.2022.2111769.
[14]	LIU H, JIA X, LUO K, et al. TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a[J]. Oncogenesis, 2022, 11(1):19. doi:10.1038/s41389-022-00392-9.
[15]	ZHANG Y, LI S, LYU Z, et al. The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients[J]. J Thorac Dis, 2022, 14(1):185-193. doi:10.21037/jtd-21-1921.
[16]	WANG X, QIN Z, QIU W, et al. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer[J]. Eur J Med Chem, 2024, 277:116711. doi:10.1016/j.ejmech.2024.116711.
[17]	CHEN Z, VALLEGA K A, CHEN H, et al. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition[J]. Pharmacol Res, 2022, 175:105998. doi:10.1016/j.phrs.2021.105998.
[18]	DEMPEK WCM, FENCHEL K. Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review[J]. Transl Cancer Res, 2024, 13(11):6540-6549. doi:10.21037/tcr-24-690.
[19]	HAO L, CHEN H, WANG L, et al. Transformation or tumor heterogeneity:Mutations in EGFR,SOX2,TP53,and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer[J]. Thorac Cancer, 2023, 14(11):1036-1041. doi:10.1111/1759-7714.14832.
[20]	CHOI Y R, KANG E H, KIM S, et al. Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer[J]. Br J Cancer, 2023, 128(12):2186-2196. doi:10.1038/s41416-023-02264-4.
[21]	BELLI S, ESPOSITO D, ASCIONE C M, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer[J]. Cancer Lett, 2024, 593:216968. doi:10.1016/j.canlet.2024.216968.
[22]	卢敏, 李鑫, 林鹏真, 等. 肿瘤蛋白p53诱导的糖酵解调节磷酸酶在恶性肿瘤中作用机制的研究进展[J]. 癌症进展, 2024, 22(19):2096-2100,2126.
	LU M, LI X, LIN P Z, et al. Research progress on the mechanism of Tumor Protein p53-induced glycolysis regulating phosphatase in malignant tumors[J]. Oncology Progress, 2024, 22(19):2096-2100,2126.
[23]	SHEN C, CHAN R, LIN B, et al. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation[J]. Theranostics, 2023, 13(13):4650-4666. doi:10.7150/thno.85855.
[24]	DESOUSAPINTO M, FONTOURA LGO, DAROSABORGES I, et al. Evaluation of infliximab-induced genotoxicity and possible action on BCL-2 and P53 genes[J]. J Toxicol Environ Health A, 2024, 87(18):752-761. doi:10.1080/15287394.2024.2368619.
[25]	DETILLEUX D, RAYNAUD P, PRADET-BALADE B, et al. The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells[J]. Elife, 2022, 11:e69705. doi:10.7554/eLife.69705.
[26]	HUANG Y, CHE X, WANG P W, et al. p53/MDM2 signaling pathway in aging,senescence and tumorigenesis[J]. Semin Cancer Biol, 2024, 101:44-57. doi:10.1016/j.semcancer.2024.05.001.
[27]	LIAO W, ZHANG R, CHEN G, et al. Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway[J]. Biomed Pharmacother, 2024, 176:116832. doi:10.1016/j.biopha.2024.116832.
[28]	CAI B, BAI Z, LIEN C, et al. NAMPT inhibitor and P73 activator represses P53 R175H mutated HNSCC cell proliferation in a synergistic manner[J]. Biomolecules, 2022, 12(3):438. doi:10.3390/biom12030438.
[29]	WANG Y, WANG L, HUANG Y, et al. Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73[J]. Acta Pharmacol Sin, 2025, 46(6):1722-1732. doi:10.1038/s41401-025-01474-1.
[30]	XIA Y, LI X, SUN W. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China[J]. Curr Gene Ther, 2020, 20(2):127-141. doi:10.2174/1566523220999200731003206.
[31]	QI L, LI G, LI P, et al. Twenty years of Gendicine^® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology[J]. Genes Dis, 2024, 11(4):101155. doi:10.1016/j.gendis.2023.101155.
[32]	TYUMENTSEVA M, TYUMENTSEV A, AKIMKIN V. CRISPR/Cas9 landscape:current state and future perspectives[J]. Int J Mol Sci, 2023, 24(22):16077. doi:10.3390/ijms242216077.
[33]	GUO C, MA X, GAO F, et al. Off-target effects in CRISPR/Cas9 gene editing[J]. Front Bioeng Biotechnol, 2023, 11:1143157. doi:10.3389/fbioe.2023.1143157.
[34]	BABU J Y M, MANOHARAN R. NUAKs facilitate mTOR-mediated NSCLC proliferation and metastasis by modulating glucose metabolism and inhibiting p53 activity[J]. Biochim Biophys Acta Mol Cell Res, 2025, 1872(3): 119922. doi:10.1016/j.bbamcr.2025.119922.